scholarly journals Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas

Oncotarget ◽  
2021 ◽  
Vol 12 (25) ◽  
pp. 2449-2458
Author(s):  
Robert Hsu ◽  
Yasmine Baca ◽  
Joanne Xiu ◽  
Rongfu Wang ◽  
J. Nicholas Bodor ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Molecular Characterization ◽  
Cancer Antigen

Abstract 660: The molecular characterization of a murine lung premalignancy model for lung cancer interception

2019 ◽  
Author(s):  
Sarah A. Mazzilli ◽  
Kahkeshan Hijazi ◽  
Riley Pihl ◽  
Anna Belkina ◽  
Xiaohui Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Molecular Characterization ◽  
Murine Lung

scholarly journals 1276P Deep molecular characterization of never smoker non-small cell lung cancer (NSCLC) patients

2021 ◽  
Vol 32 ◽  
pp. S995
Author(s):  
C. Dellepiane ◽  
G. De Luca ◽  
M. Tagliamento ◽  
S. Coco ◽  
G. Rossi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Molecular Characterization ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients ◽  
Never Smoker

Clinical, pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer: A multicenter experience in Madrid.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21128-e21128
Author(s):  
Maria Sereno ◽  
Sandra Falagan ◽  
Juan Moreno-Rubio ◽  
Rosa Maria Alvarez Alvarez ◽  
Maria Eugenia Olmedo Garcia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Molecular Characterization ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Long Term Survivors

scholarly journals Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration

Oncotarget ◽  
2017 ◽  
Vol 8 (65) ◽  
pp. 109818-109835 ◽  
Author(s):  
Lei Wang ◽  
Coraline Dumenil ◽  
Catherine Julié ◽  
Violaine Giraud ◽  
Jennifer Dumoulin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Cells ◽  
Molecular Characterization ◽  
Circulating Tumor Cells

scholarly journals Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy

Cancers ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 749 ◽  
Author(s):  
Oronzo Brunetti ◽  
Giuseppe Badalamenti ◽  
Simona De Summa ◽  
Angela Calabrese ◽  
Antonella Argentiero ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Molecular Characterization ◽  
Progression Free Survival ◽  
Small Cell ◽  
Ductal Adenocarcinoma ◽  
Multiple Primary Cancers ◽  
Common Mutation ◽  
Second Line

The management of multiple primary cancers, an event not so infrequent in oncology practice, is a critical issue due to the lack of literature. In this study, we reported the case of a patient with non-small cell metastatic lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in combination with gemcitabine plus nab-paclitaxel and with mFOLFOX6 in first and second line, respectively. It achieved a progression-free survival and a28-months overall survival (OS) for NSCLC and PFS-1 and OS of 20 and 13 months, respectively for PDAC. Moreover, the combination of gefitinib and chemotherapy treatmentsshowed a good safety profile. Given the insignificant frequency of this case, we performed a molecular characterization of both neoplasms with the aim to investigate the existence of particular activated pathways and/or similar immunological mutations. It is interesting to note that two neoplasms shared a common mutation ofthe B7-H3 gene, with the consecutive impairment of its expressed protein. In both PDAC and NSCLC, the expression of this protein was associated with a worse survival rate. Since B7-H3 is an anti-apoptotic protein, the reduction of its expression or function should justify a pro-apoptotic activity with a leading justification of the long survival of the patient considered in this report.

Sign in / Sign up

Export Citation Format

Share Document